Primary peritoneal carcinoma is a rare peritoneal epithelial malignancy that resembles high-grade serous ovarian carcinoma in histology and treatment approach.
The FDA has approved Agilent's PD-L1 IHC 22C3 pharmDx as a companion diagnostic for identifying esophageal cancer patients eligible for Merck's KEYTRUDA immunotherapy. This marks the eighth FDA-approved indication for this diagnostic test with KEYTRUDA. The test helps identify patients whose tumors express PD-L1 for potential treatment with the anti-PD-1 therapy.
Barclays initiated coverage on Merck with an overweight rating and $140 price target, citing expected product launches including enlicitide and pivotal trial readouts for tulisokibart in 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07495124 |
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence |
NOT_YET_RECRUITING | PHASE2 |
| NCT07480954 |
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) |
RECRUITING | PHASE1/PHASE2 |
| NCT07285044 |
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas |
RECRUITING | PHASE2 |
| NCT07269574 |
Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance |
NOT_YET_RECRUITING | |
| NCT07118176 |
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers |
RECRUITING | PHASE1 |
| NCT07023484 |
Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer |
RECRUITING | PHASE2 |
| NCT06972693 |
NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT06915025 |
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer |
RECRUITING | PHASE3 |
| NCT06870539 |
Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment |
COMPLETED | |
| NCT06726330 |
Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer |
NOT_YET_RECRUITING | NA |
